sign in sign up
<<
Home , Amgen

AMGEN UNLOCKING THE POTENTIAL OF BIOLOGY FOR PATIENTS OUR MISSION To serve patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. OUR ASPIRATION

We aspire to be the best human therapeutics company. We will live the Amgen Values and use science and innovation to dramatically improve people’s lives.

AMGEN VALUES

Be science-based Compete intensely and win Create value for patients, staff and stockholders Be ethical Trust and respect each other Ensure quality Work in teams Collaborate, communicate and be accountable DAWN OF THE BIO-CENTURY

Never before have we been in a better position to understand and combat human disease. Biotechnology has evolved rapidly in the past three decades. And yet we remain an industry in its infancy, which means we have only begun to realize the full potential of biotechnology and how it can benefit human health.

Many of the past century’s breakthrough innovations were in the areas of physics and information technology. We believe we have entered an exciting new era—the Bio-Century—where there is great potential for new discoveries as we gain a deeper understanding of human biology and biotechnology.

Major advances in DNA sequencing and gene therapy are leading to exciting opportunities in discovery research. We also see growing global demand for biologic medicines on the horizon due to factors ranging from greater access to healthcare to aging populations to new kinds of cancer treatments. And investments are being made based on extensive knowledge of biologics manufacturing to improve existing processes and technologies to help further optimize the outcomes we deliver to patients.

Amgen is well positioned to break new ground in our industry—at the dawn of the Bio-Century—and serve more patients with our therapeutics worldwide. Never before have we been in a better position to understand and combat human disease. WHAT WE DO

PIONEERING MEDICINES We have a presence in approximately 100 countries worldwide and have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Our medicines typically address diseases for which the number of effective treatment options is limited, or they are medicines that provide a viable option to what is otherwise available. INNOVATIVE RESEARCH Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen’s discovery research efforts—and a major contributor to the development of Amgen’s deep and broad pipeline of potential new medicines. Amgen’s “biology first” approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. As advances in human genetics continue to shed new light on the molecular roots of disease, Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

WORLD-CLASS MANUFACTURING The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

For more information about our world-class manufacturing, visit biotechnologybyamgen.com. OUR HERITAGE

CULTURE OF SCIENCE AND INNOVATION The story of Amgen began more than three decades ago with a simple idea—that emerging research in genetics could lead to very exciting opportunities if the right scientists could be assembled and given the appropriate resources. Amgen has since grown to be the world’s largest independent biotechnology company, launching some of the biotechnology industry’s first blockbuster therapies, and subsequently changing the course of medicine. As a company, we could not have accomplished what we did were it not for our commitment to building a culture that embraces science and innovation—a culture that continues to shape who we are today.

DELIVERING FOR PATIENTS Amgen is counted among the early pioneers of biologic medicines. Our therapies have since reached millions of patients worldwide. Our scientists have characterized key biologic processes that have led to the development of innovative, first-in-class therapies. We have shaped the scientific world’s understanding of certain disease processes. We have also engineered new types of therapeutic platforms.

AMGEN FOUNDATION The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated more than $250 million in grants to local, regional and international nonprofit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, Amgen Biotech Experience, and Amgen Teach. For more information, visit www.AmgenInspires.com. The story of Amgen began more than three decades ago with a simple idea— that emerging research in genetics could lead to very exciting opportunities if the right scientists could be assembled and given the appropriate resources. KEY MILESTONES

1980 Amgen is established in 2004 Sensipar®/Mimpara® (cinacalcet) is 2014 Amgen Singapore Manufacturing Thousand Oaks, California approved Pte. Ltd. construction is completed

1983 Amgen employee Fu-Kuen Lin clones 2006 Vectibix® () is approved Asia Research and Development gene Center opened in Shanghai, China 2008 Nplate® () is approved 1985 Research team at Amgen clones BLINCYTO® () is granulocyte colony-stimulating 2010 Prolia® () and XGEVA® approved factor (G-CSF) (denosumab) are approved 2015 Corlanor® (ivabradine) is approved 1989 EPOGEN® () is approved 2012 deCODE Genetics, a global leader in human genetics, is acquired Repatha® () is approved 1991 NEUPOGEN ® () is approved Micromet, Inc., is acquired IMLYGIC® (talimogene laherparepvec) 2001 Aranesp® () is is approved approved 2013 Amgen-Betta Pharmaceuticals joint venture established in China 2002 Immunex, developer of Enbrel® (), is acquired Amgen Astellas BioPharma K.K. announces Japan alliance Neulasta® () is approved Onyx Pharmaceuticals is acquired PRODUCTS

Aranesp® (darbepoetin alfa) NEUPOGEN® (filgrastim) BLINCYTO® (blinatumomab) Nplate® (romiplostim) Corlanor® (ivabradine) Prolia® (denosumab) Enbrel® (etanercept) Repatha® (evolocumab) EPOGEN® (epoetin alfa) Sensipar® / Mimpara® IMLYGIC® (cinacalcet) (talimogene laherparepvec) Vectibix® (panitumumab) KYPROLIS® () XGEVA® (denosumab) Neulasta® (pegfilgrastim)

For information about our pipeline and therapies, visit www.amgen.com. Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320-1799 www.amgen.com

© 2016 Amgen Inc. All rights reserved. August 2016.